Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019

BACKGROUND: The combination aztreonam/avibactam is currently under Phase 3 trials for the treatment of serious infections caused by Gram-negative bacteria including those with MBLs. OBJECTIVES: To investigate the resistance mechanisms in Enterobacterales exhibiting aztreonam/avibactam MICs of ≥4 mg/...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendes, Rodrigo E, Doyle, Timothy B, Streit, Jennifer M, Arhin, Francis F, Sader, Helio S, Castanheira, Mariana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561256/
https://www.ncbi.nlm.nih.gov/pubmed/34436603
http://dx.doi.org/10.1093/jac/dkab279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561256/
https://www.ncbi.nlm.nih.gov/pubmed/34436603
http://dx.doi.org/10.1093/jac/dkab279

Ejemplares similares